News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cortex Biochem, Inc. And Bouty S.p.A. Sign Exclusive Distribution Agreement; Bouty To Market Cortex Biochem Inc.'s MagaZorb Nucleic Acid Isolation Kits In Italy



10/19/2005 5:08:54 PM

RALEIGH, N.C.--(BUSINESS WIRE)--June 14, 2005--Cortex Biochem(TM) Inc., a global leader in developing magnetic particle technology and products used in genomic research and clinical diagnostics, has established an exclusive distribution and limited license agreement with Bouty S.p.A. of Milan, Italy. Effective January of this year, the agreement allows Bouty and Bouty's subsidiary Biotechnology Division, Technogenetics S.r.l., to promote, market and sell Cortex Biochem(TM) Inc.'s MagaZorb(R) Nucleic Acid Isolation Kits and associated reagents in Italy. "We are very excited about our agreement with Bouty, which launches our selling efforts of MagaZorb(R) in Europe," said Matt Pourfarzaneh, President and CEO of Cortex Biochem(TM) Inc. "We are confident that this is the ideal partnership to firmly establish our technology in the European market. We anticipate progressive market penetration since MagaZorb(R) provides greater value with better performing, faster, flexible nucleic acid isolation.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES